Enbrel Safety Data For Up To 8 Years In Patients With Juvenile Rheumatoid Arthritis
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), have announced the presentation of additional data that showed that the safety profile of Enbrel (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy. JRA is a chronic autoimmune disease of childhood that is sometimes difficult to diagnose. [click link for full article]
Best Way To See Damage In Knee Osteoarthritis Is To Measure Joint Space Width In Semi-Flexed Knee
Taking x-rays of the semi-flexed knee is the most accurate way of evaluating structural damage in patients with knee osteoarthritis (OA) according to results presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.In knee OA, there are several radiographic views from which structural damage can be identified and several tools from which damage to the knee can be assessed. [click link for full article]
Disease Severity Is Directly Related To National Health Expenditure For Rheumatoid Arthritis
In the first international ‘map of rheumatoid arthritis’ (RA), spanning Europe and beyond, significant national differences in RA severity can be directly traced to national economics, most notably health expenditure, as exposed by data from the QUEST-RA Study presented at EULAR 2007, the Annual Congress of the European League Against Rheumatism, Barcelona, Spain. [click link for full article]
